Appendix 2. Template for risk assessment and summary of advice given
Updated 16 July 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/malaria-prevention-guidelines-for-travellers-from-the-uk-2026/appendix-2-template-for-risk-assessment-and-summary-of-advice-given
A risk assessment should be performed when an antimalarial is prescribed. This also applies to an over-the-counter sale of a pharmacy-only medicine. For the atovaquone plus proguanil product, the manufacturers provide a pharmacist checklist which can usefully be used as part of such an assessment. The UK Malaria Expert Advisory Group (UKMEAG) advises that a risk assessment for malaria chemoprophylaxis should be performed or checked by the pharmacist, is described specifically in the pharmacy standard operating procedures and a record be kept of the outcome of such an assessment. These principles should also apply to sales over the internet through registered e-pharmacies where an appropriate on-line risk assessment is conducted.
The template which forms part of the email enquiry service is a useful tool to guide practitioners when risk assessing their traveller going to a malarious area and requiring malaria prevention advice in any consultation, irrespective of the service delivery, such as face to face or online. The General Medical Council (GMC) provides . The form may be adapted for the particular circumstances of individual clinical settings. Risk materials are also produced for and
Note: The information needed to complete this template and thus make a full risk assessment should be used in any consultation for malaria prevention, whether conducted face-to-face or via e-prescribing.